Skip to main content
    X

    XBiotech Inc (XBIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.85
    -0.11 (-5.61%)

    Market Cap: $59.76M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    XBiotech Inc (XBIT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    XBiotech reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$45.54M, operating cash flow was -$39.92M and free cash flow was -$40.21M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.46M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $55.69M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$4.01M-78.2%83.8%-860.1%-820.4%
    Dec 2021$18.39M-58.2%68.4%-136.4%-94.7%
    Dec 2020$44.00MN/A21.5%-41.5%-25.5%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$4.01M$18.39M$44.00M$0$0$0$0
    Cost of revenue$0$0$0$651.00K$5.82M$34.55M$0$0$0$0
    Gross profit$0$0$0$3.36M$12.57M$9.45M$0$0$0$0
    Research and development$47.39M$37.76M$32.85M$31.54M$28.27M$9.53M$24.09M$15.72M$26.42M$42.49M
    Operating income-$55.69M-$42.47M-$37.51M-$34.49M-$25.08M-$18.28M-$31.23M-$20.99M-$34.06M-$52.76M
    Net income-$45.54M-$38.53M-$24.56M-$32.90M-$17.41M-$11.22M$668.63M-$21.14M-$33.15M-$52.76M
    EBITDA-$49.21MN/A-$32.99MN/A-$23.28M-$13.04M$720.25M-$19.11M-$32.02M-$52.11M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0$2.62M
    Gross profit$0$0$0-$378.00K$0$0$0N/A$0$0$0$2.19M
    Operating income-$5.32M-$6.15M-$6.27M-$29.75M-$6.05M-$6.34M-$13.55M-$8.75M-$7.90M-$14.97M-$10.85M-$8.59M
    Net income-$4.46M-$6.73M-$5.50M-$26.89M-$6.01M-$1.76M-$10.88M-$10.51M-$5.01M-$13.01M-$10.00M-$4.63M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $125.55M were 83.7% of total assets of $150.08M, against total liabilities of $9.73M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$150.08M$199.09M$226.62M$246.10M$275.18M$353.74M$816.88M$44.34M$62.97M$67.05M
    Current assets$126.95M$174.57M$201.72M$219.84M$246.87M$325.88M$716.26M$17.02M$33.33M$36.93M
    Cash and equivalents$125.55M$172.68M$200.02M$157.31M$236.98M$237.37M$714.59M$15.82M$31.77M$34.32M
    Total liabilities$9.73M$16.82M$7.77M$5.70M$5.79M$5.11M$61.25M$2.95M$2.81M$7.99M
    Short-term debtN/A$10.25M$0N/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$140.35M$182.27M$218.85M$240.40M$269.38M$348.64M$755.63M$41.40M$60.16M$59.06M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$128.61M$133.65M$139.84M$150.08M$172.42M$178.68M$181.86M$199.09M$209.85M$215.56M$227.86M$227.24M
    Total liabilities$4.55M$5.19M$4.82M$9.73M$5.34M$5.62M$7.15M$16.82M$17.74M$18.85M$18.58M$8.40M
    Cash and equivalents$105.04M$109.53M$115.46M$125.55M$147.37M$152.94M$155.90M$172.68M$183.12M$188.53M$201.04M$200.02M
    Shareholder equity$124.06M$128.46M$135.02M$140.35M$167.08M$173.06M$174.71M$182.27M$192.12M$196.70M$209.28M$218.85M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$39.92M-$30.96M-$18.73M-$14.82M$69.44M-$65.15M-$18.27M-$16.54M-$33.65M-$46.02M
    Capital expenditures$289.00K$1.30M$362.00K$585.00K$3.52M$3.73M$204.00K$122.00K$1.41M$4.75M
    Free cash flow-$40.21M-$32.27M-$19.09M-$15.41M$65.92M-$68.88M-$18.47M-$16.66M-$35.05M-$50.76M
    Dividends paidN/AN/AN/A$0$75.00M$0$0$75.00M$0$0
    Share repurchasesN/AN/A$14.00K$0N/A$420.00M$38.06MN/AN/AN/A
    Investing cash flow-$289.00K-$1.30M$61.50M-$63.89M-$3.52M-$3.73M$674.80M-$122.00K-$1.41M-$13.91M
    Financing cash flow-$10.25M$10.45M-$9.00K$0-$67.01M-$409.72M$42.10M$201.00K$33.32M$2.94M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.52M-$4.51M-$8.97M-$22.95M-$4.26M-$5.99M-$6.72M-$6.54M-$5.84M-$11.38M-$7.20M-$3.43M
    Capital expenditures$12.00KN/A$0$34.00K$110.00K$51.00K$94.00K$78.00K$344.00K$627.00K$255.00K$115.00K
    Free cash flow-$4.53MN/A-$8.97M-$22.99M-$4.37M-$6.04M-$6.81M-$6.62M-$6.19M-$12.00M-$7.46M-$3.55M
    Last 12 quarters

    Frequently Asked Questions About XBIT

    What is XBiotech's annual revenue?

    XBiotech reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is XBiotech profitable?

    No. XBiotech reported net income of -$45.54M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does XBIT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$39.92M minus capital expenditures of $289.00K produced free cash flow of -$40.21M.

    How much debt does XBiotech have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $125.55M.